Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
* Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus
* The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics
* The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus
* To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria:
1. Ovarian Cancer Cohorts Only: Patients with histologically or cytologically confirmed diagnosis of advanced, epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer who have all of the following:
1. serum CA-125 level ≥2 x upper limit of normal (ULN) (in screening, not required for low-grade serous carcinoma)
2. has received at least 1 line of platinum-containing therapy or must be platinum-intolerant (applicable for dose escalation and non-randomized dose expansion cohorts)
3. documented relapse or progression on or after the most recent line of therapy
4. no standard therapy options likely to convey clinical benefit
2. Adequate organ and bone marrow function as defined in the protocol
3. Life expectancy of at least 3 months
4. Randomized phase 2 expansion cohort (Ovarian Cancer only): Platinum-resistant ovarian cancer patients who have had 2 to 4 lines of platinum-based therapy as defined in the protocol.
5. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-Programmed Cell Death Ligand 1 (PD-1) therapy and platinum-based chemotherapy:
1. MUC16 positivity of tumor cells ≥25% by immunohistochemistry (IHC), as defined in the protocol
2. 1-4 prior lines of systemic therapy, as described in the protocol
Key Exclusion Criteria:
1. Prior treatment with anti-Programmed Cell Death (PD-1)/PD-L1 therapy, as described in the protocol
2. Ovarian Cancer Expansion cohorts only: More than 4 prior lines of cytotoxic chemotherapy (does not apply to low-grade serous ovarian cancer cohort)
3. Prior treatment with a MUC16 - targeted therapy
4. Untreated or active primary brain tumor, central nervous system (CNS) metastases, or spinal cord compression, as described in the protocol
5. History and/or current cardiovascular disease, as defined in the protocol
6. Severe and/or uncontrolled hypertension at screening. Patients taking anti-hypertensive medication must be on a stable anti-hypertensive regimen
Note: Other protocol-defined Inclusion/Exclusion Criteria apply
Primary outcome measure(s)
Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy — From Cycle 1, Day 1 up to 35 days Dose Escalation Phase
Number of participants with DLTs for ubamatamab with cemiplimab — From Cycle 2, Day 1 up to 21 days Dose Escalation Phase
Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for ubamatamab monotherapy — Up to 2 years Dose Escalation Phase
Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimab — Up to 2 years Dose Escalation Phase
Number of participants with serious adverse events (SAEs) for ubamatamab monotherapy — Up to 2 years Dose Escalation Phase
Number of participants with SAEs for ubamatamab with cemiplimab — Up to 2 years Dose Escalation Phase
Number of deaths for ubamatamab monotherapy — Up to 2 years Dose Escalation Phase
Number of deaths for ubamatamab with cemiplimab — Up to 2 years Dose Escalation Phase
Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for ubamatamab monotherapy — Up to 2 years Dose Escalation Phase
Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab with cemiplimab — Up to 2 years Dose Escalation Phase
Concentration of ubamatamab in serum over time for ubamatamab monotherapy — Up to 2 years Dose Escalation Phase
Concentration of ubamatamab in serum over time for ubamatamab with cemiplimab — Up to 2 years Dose Escalation Phase
Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for ubamatamab monotherapy — Up to 2 years Dose Expansion Phase
ORR defined by RECIST 1.1 for ubamatamab with cemiplimab — Up to 2 years Dose Expansion Phase
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.